drugset
Drugs / IL-4
last change Jan 2026 re-read 9 days ago

IL-4

Protein / enzyme biologic

Trials 0

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Comparator or background therapy2 trials
Phase 1/2 NCT00923910 Background Feb 2008 → Oct 2013 acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome National Cancer Institute (NCI) Completed No outcome recorded
Phase 2 NCT00001564 Background Dec 1996 → Oct 2007 Ewing sarcoma, rhabdomyosarcoma National Cancer Institute (NCI) Completed No outcome recorded

News releases announcing trial results or a regulatory action · 4

DateIssuerRelease
2026-01-08 GRI Bio Operations, Inc. Results GRI Bio Announces Additional Positive Data from Phase 2a Study in Idiopathic Pulmonary Fibrosis, Strengthening Clinical Proof-of-Concept for GRI-0621 gribio.com ↗
T cell subsets demonstrated increased type I-associated cytokines (IFN-γ) and reduced type 2 (IL-4 and IL-13) and type 3-associated cytokines (IL-17A and IL-22) in both BAL and PBMC samples.
2022-06-14 Aurealis Oy Results Aurealis Therapeutics successfully completes treatment period of its AUP-16 Phase 1 study in non-healing Diabetic Foot Ulcers: 83% patients receiving lead therapeutic dose achieved complete healing aurealistherapeutics.com ↗
We are extremely delighted about the efficacy data, as 83% of the patients receiving the lead therapeutic dose reached complete healing
2022-03-01 Aurealis Oy Results Aurealis Therapeutics publishes first study on four-in-one -combination therapy using live lactococcus lactis expressing three human therapeutic proteins for the treatment of chronic non-healing wounds aurealistherapeutics.com ↗
We’re really proud to see that this study shows how the combination of the individual components on the wound microenvironment initiates and improves healing in chronic wounds.
2019-09-27 Aurealis Oy Regulatory Aurealis Therapeutics receives Clinical Trial Application approval for AUP-16 Phase 1 DFU study aurealistherapeutics.com ↗

All press releases naming this drug 4 releases

DateIssuerRelease

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as IL-4 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00923910 ↗
1

NCT00001564 ↗
Modality Protein / enzyme biologic “water-soluble protein; this study will use GMCSF (granulocyte macrophage colony stimulating factor)/IL-4 generated monocyte derived dendritic cells” NCT00923910 ↗